Literature DB >> 33586773

Challenges and Promise of Human Immunodeficiency Virus Remission.

Yijia Li1, Abbas Mohammadi1, Jonathan Z Li1.   

Abstract

Antiretroviral therapy effectively controls human immunodeficiency virus (HIV) replication but it is unable to fully eradicate the HIV reservoir and treatment must be life-long. Progress toward a strategy for HIV remission will require overcoming key hurdles to fill gaps in our understanding of HIV persistence, but the identification of individuals who have attained sterilizing or functional HIV cure show that such a goal is achievable. In this review, we first outline challenges in targeting the HIV reservoir, including difficulties identifying HIV-infected cells, ongoing work elucidating the complex intracellular environment that contribute to HIV latency, and barriers to reactivating and clearing the HIV reservoir. We then review reported cases of HIV sterilizing cure and explore natural models of HIV remission and the promise that such HIV spontaneous and posttreatment controllers may hold in our search for a broadly-applicable strategy for the millions of patients living with HIV.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV reservoir; latency; post-treatment controller; provirus; spontaneous controller

Mesh:

Substances:

Year:  2021        PMID: 33586773      PMCID: PMC8171803          DOI: 10.1093/infdis/jiaa568

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  113 in total

1.  Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques.

Authors:  Zachary Strongin; Luca Micci; Rémi Fromentin; Justin Harper; Julia McBrien; Emily Ryan; Neeta Shenvi; Kirk Easley; Nicolas Chomont; Guido Silvestri; Mirko Paiardini
Journal:  J Virol       Date:  2020-07-01       Impact factor: 5.103

2.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.

Authors:  Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

3.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Authors:  Zhen Wang; Qinghua Pan; Patrick Gendron; Weijun Zhu; Fei Guo; Shan Cen; Mark A Wainberg; Chen Liang
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

4.  Hematopoietic cell transplantation with cord blood for cure of HIV infections.

Authors:  Lawrence D Petz; Istvan Redei; Yvonne Bryson; Donna Regan; Joanne Kurtzberg; Elizabeth Shpall; Jonathan Gutman; Sergio Querol; Pamela Clark; Richard Tonai; Sarah Santos; Aide Bravo; Stephen Spellman; Loren Gragert; John Rossi; Shirley Li; Haitang Li; David Senitzer; John Zaia; Joseph Rosenthal; Stephen Forman; Robert Chow
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-23       Impact factor: 5.742

5.  Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Authors:  Rajesh T Gandhi; Deborah K McMahon; Ronald J Bosch; Christina M Lalama; Joshua C Cyktor; Bernard J Macatangay; Charles R Rinaldo; Sharon A Riddler; Evelyn Hogg; Catherine Godfrey; Ann C Collier; Joseph J Eron; John W Mellors
Journal:  PLoS Pathog       Date:  2017-04-20       Impact factor: 6.823

6.  Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure.

Authors:  Concepcion Casado; Cristina Galvez; Maria Pernas; Laura Tarancon-Diez; Carmen Rodriguez; Víctor Sanchez-Merino; Mar Vera; Isabel Olivares; Rebeca De Pablo-Bernal; Alberto Merino-Mansilla; Jorge Del Romero; Ramon Lorenzo-Redondo; Ezequiel Ruiz-Mateos; María Salgado; Javier Martinez-Picado; Cecilio Lopez-Galindez
Journal:  Sci Rep       Date:  2020-02-05       Impact factor: 4.379

7.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

Authors:  N M Archin; A L Liberty; A D Kashuba; S K Choudhary; J D Kuruc; A M Crooks; D C Parker; E M Anderson; M F Kearney; M C Strain; D D Richman; M G Hudgens; R J Bosch; J M Coffin; J J Eron; D J Hazuda; D M Margolis
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

8.  The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Patrick M Tarwater; Joel N Blankson
Journal:  EBioMedicine       Date:  2016-04-18       Impact factor: 8.143

9.  Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.

Authors:  Pavitra Roychoudhury; Harshana De Silva Feelixge; Daniel Reeves; Bryan T Mayer; Daniel Stone; Joshua T Schiffer; Keith R Jerome
Journal:  BMC Biol       Date:  2018-07-11       Impact factor: 7.364

10.  Transplantation of CCR5∆32 Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection.

Authors:  Meghan Rothenberger; John E Wagner; Ashley Haase; Douglas Richman; Bartosz Grzywacz; Matthew Strain; Steven Lada; Jacob Estes; Courtney V Fletcher; Anthony T Podany; Jodi Anderson; Thomas Schmidt; Steve Wietgrefe; Timothy Schacker; Michael R Verneris
Journal:  Open Forum Infect Dis       Date:  2018-05-22       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.